EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]
Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing o...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/41acde07226d49a9b1fe02a82eac6b89 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”. The authors apologize for these errors.Read the original article |
|---|